Literature DB >> 19721443

Rheumatoid arthritis market.

Jeffrey G Stoll, Uma Yasothan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19721443     DOI： 10.1038/nrd2947

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  8 in total

1.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Authors:  Lars Klareskog; Désirée van der Heijde; Julien P de Jager; Andrew Gough; Joachim Kalden; Michel Malaise; Emilio Martín Mola; Karel Pavelka; Jacques Sany; Lucas Settas; Joseph Wajdula; Ronald Pedersen; Saeed Fatenejad; Marie Sanda
Journal:  Lancet       Date:  2004-02-28       Impact factor: 79.321

2.  Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.

Authors:  M Weinblatt; B Combe; A Covucci; R Aranda; J C Becker; E Keystone
Journal:  Arthritis Rheum       Date:  2006-09

3.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

4.  The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

Authors:  Joel M Kremer; Bradley J Bloom; Ferdinand C Breedveld; John H Coombs; Mark P Fletcher; David Gruben; Sriram Krishnaswami; Rubén Burgos-Vargas; Bethanie Wilkinson; Cristiano A F Zerbini; Samuel H Zwillich
Journal:  Arthritis Rheum       Date:  2009-07

5.  Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.

Authors:  Josef S Smolen; Désirée M F M Van Der Heijde; E William St Clair; Paul Emery; Joan M Bathon; Edward Keystone; Ravinder N Maini; Joachim R Kalden; Michael Schiff; Daniel Baker; Chenglong Han; John Han; Mohan Bala
Journal:  Arthritis Rheum       Date:  2006-03

Review 6.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

7.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01

8.  Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.

Authors:  Michael E Weinblatt; Arthur Kavanaugh; Ruben Burgos-Vargas; Ara H Dikranian; Gabriel Medrano-Ramirez; Jorge L Morales-Torres; Frederick T Murphy; Theresa Kane Musser; Nicholas Straniero; Angela V Vicente-Gonzales; Elliott Grossbard
Journal:  Arthritis Rheum       Date:  2008-11
  8 in total
  5 in total

1.  Xiaoyao-Qingluoyin Cure Adjuvant-Induced Arthritis by Easing LPS Response-Related Pathway-Mediated Immune Abnormality.

Authors:  Dan-Feng Li; Chen-Qiong Xie; Yi-Jin Wu; Chao Shi; Chao-Fan Ji; Yi-Fang Hu; Qiang Liao; Yan Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-25       Impact factor: 2.650

2.  Design, synthesis and evaluation of (R)-3-(7-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.

Authors:  Chieyeon Chough; Sunmin Lee; Misuk Joung; Jaemin Lee; Jong Hoon Kim; B Moon Kim
Journal:  Medchemcomm       Date:  2018-01-15       Impact factor: 3.597

3.  Arthroplasty Rates Not Increasing in Young Patients With Rheumatoid Arthritis: A National Database Review, 2005 Versus 2014.

Authors:  John F Nettrour; Bradley S Bailey; Major B Burch; Devin D Clair; Rayford R June; Nancy J Olsen; Djibril M Ba; Guodong Liu; Douglas L Leslie
Journal:  Arthroplast Today       Date:  2021-03-10

4.  Inflammation-Triggered Supramolecular Nanoplatform for Local Dynamic Dependent Imaging-Guided Therapy of Rheumatoid Arthritis.

Authors:  Luoyuan Li; Xuelong Wang; Rongyao Gao; Bei Zhang; Yuxin Liu; Jing Zhou; Limin Fu; Jian Wang
Journal:  Adv Sci (Weinh)       Date:  2022-01-12       Impact factor: 16.806

5.  Cell-penetrating peptides released from thermosensitive nanoparticles suppress pro-inflammatory cytokine response by specifically targeting inflamed cartilage explants.

Authors:  Rush L Bartlett; Shaili Sharma; Alyssa Panitch
Journal:  Nanomedicine       Date:  2012-10-03       Impact factor: 5.307
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.